The role of sclerostin in the development and progression of cardiovascular diseases- a potential biomarker?
Advances in Medical Sciences · 2025-10 · 70 (2) · 436-443
DOI: 10.1016/j.advms.2025.10.003 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advances in Medical Sciences, 2025-10. Verfasst von Sebastian Stelmaszek und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology and Internal Medicine with Intensive Cardiac Care Unit, Medical University of Bialystok, Bialystok, Poland. Electronic addre…. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Adaptor Proteins, Signal Transducing, Biomarkers. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben.
Abstract (Originalsprache)
Sclerostin, a glycoprotein primarily synthesized by osteocytes, is a key regulator of bone remodeling through its inhibition of the Wnt/β-catenin signaling pathway. Beyond its established role in bone metabolism, sclerostin has been identified in vascular tissues, including smooth muscle cells of blood vessels, suggesting a potential role in cardiovascular diseases (CVD). Research on sclerostin's role in CVD has yielded conflicting results, highlighting its complex involvement in vascular calcification and atherosclerosis. Some studies associate elevated sclerostin levels with a reduced risk of cardiovascular events, potentially due to its inhibition of pathways driving vascular calcification and osteogenic transformation of vascular cells. Conversely, other research links higher sclerostin levels with increased cardiovascular risk, including atherosclerosis, myocardial infarction, and stroke, possibly reflecting a compensatory response to vascular damage or inflammation. Discrepancies in findings may stem from differences in study populations, methodologies, and confounding factors such as age, renal function, and medication use. Furthermore, sclerostin's dual effects may depend on specific pathological contexts, complicating its interpretation as a biomarker. This review examines the evidence for sclerostin's role in CVD and its potential utility as a biomarker for cardiovascular risk stratification. While emerging data suggest diagnostic and therapeutic relevance, particularly in populations with chronic kidney disease or metabolic disorders, further research is necessary to elucidate its mechanisms, identify modulating factors, and assess its clinical value. A clearer understanding of sclerostin's vascular effects could pave the way for novel approaches to cardiovascular disease prevention and management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology and Internal Medicine with Intensive Cardiac Care Unit, Medical University of Bialystok, Bialystok, Poland. Electronic address: sebastian.stelmaszek@sd.umb.edu.pl.
- Department of Cardiology and Internal Medicine with Intensive Cardiac Care Unit, Medical University of Bialystok, Bialystok, Poland.
Zitieren
APA
Stelmaszek, S., Tarasiuk, E., Knapp, M., Kazimierczyk, R., & Lisowska, A. (2025). The role of sclerostin in the development and progression of cardiovascular diseases- a potential biomarker?. Advances in Medical Sciences, 70(2), 436-443. https://doi.org/10.1016/j.advms.2025.10.003
Vancouver
Stelmaszek S, Tarasiuk E, Knapp M, Kazimierczyk R, Lisowska A. The role of sclerostin in the development and progression of cardiovascular diseases- a potential biomarker?. Advances in Medical Sciences. 2025;70(2):436-443. doi:10.1016/j.advms.2025.10.003
BibTeX
@article{Stelmaszek2025,
author = {Stelmaszek, Sebastian and Tarasiuk, Ewa and Knapp, Małgorzata and Kazimierczyk, Remigiusz and Lisowska, Anna},
title = {The role of sclerostin in the development and progression of cardiovascular diseases- a potential biomarker?},
journal = {Advances in Medical Sciences},
year = {2025},
volume = {70},
number = {2},
pages = {436--443},
doi = {10.1016/j.advms.2025.10.003}
}
EUVIMED